Mebanazine (trade name Actomol) is a monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was previously used as an antidepressant in the 1960s, but has since been withdrawn due to hepatotoxicity.[1][2][3]

Mebanazine
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 1-phenylethylhydrazine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.559 Edit this at Wikidata
Chemical and physical data
FormulaC8H12N2
Molar mass136.198 g·mol−1

Mebanazine in animals is claimed to be a more potent MAOI than pheniprazine with a greater therapeutic index.[4]

See also

edit

References

edit
  1. ^ Gilmour SJ (September 1965). "Clinical trial of mebanazine--a new monoamine oxidase inhibitor". The British Journal of Psychiatry. 111 (478): 899–902. doi:10.1192/bjp.111.478.899. PMID 5889715. S2CID 46651861.
  2. ^ Barker JC, Jan IA, Enoch MD (November 1965). "A controlled trial of mebanazine ('Actomol') in depression". The British Journal of Psychiatry. 111 (480): 1095–100. doi:10.1192/bjp.111.480.1095. PMID 5320546. S2CID 6803488.
  3. ^ Knott F (1965). "A preliminary trial of mebanazine in depressive states". The Journal of New Drugs. 5 (6): 345–7. doi:10.1002/j.1552-4604.1965.tb00259.x. PMID 5327282.
  4. ^ Biel, J. H. (1967). "Annual Reports in Medicinal Chemistry". Chapter 2. Antidepressants, Stimulants, Hallucinogens. Annual Reports in Medicinal Chemistry. Vol. 2. Elsevier. pp. 11–23. doi:10.1016/S0065-7743(08)61499-2. ISBN 9780120405022.